Daxor Corporation Announces Presentation Of Data From Phase I NIH-Sponsored Trial At American Heart Association Annual Meeting
dxr
dxr
Save time and jump to the most important pieces.
Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00
N-PX - DAXOR CORP (0000027367) (Filer)
N-CSRS - DAXOR CORP (0000027367) (Filer)
40-17G - DAXOR CORP (0000027367) (Filer)
Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence Oak Ridge, TN, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Conference being held at the Gaylord Rockies Resort & Convention Center in Aurora, CO, October 17-19, 2024. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting cardiovascular thought-leaders from across the country to transform cardiovascular care together with leading industry innovators. "We look forward to engaging with i
Oak Ridge, TN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Maxim Director of Research and Senior Healthcare Analyst Anthony Vendetti. The summit is being held from October 15 – 17, 2024. Event:Fireside Chat at 2024 Maxim Healthcare Virtual SummitDate:Tuesday, October 15, 2024Time:10:00 AM ETWebcast:https://m-vest.com/events/healthcare-10152024 Mr. Feldschuh will be available for one-on-one meetings with registered investors of the summit. Interested investors may also
Company to Focus on 510(k) Approval Path, Accelerating Time-to-Market Oak Ridge, TN, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces a strategic update to its regulatory approach for its novel diagnostic blood volume analyzer platform. Following productive discussions with the U.S. Food and Drug Administration (FDA), the company has decided to withdraw its current dual 510(k)/CLIA-waiver application and resubmit a focused 510(k) application. This decision comes after considerable progress in addressing key regulatory considerations and aims to expedite the approval process, potentially bringing t
Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer. As part of his new responsibilities, Dr. Jefferies will leverage his extensive expertise to advise Daxor on strategic clinical and medical affairs matters and to facilitate the collaboration between the Company and healthcare professionals. He will be a key advisor, offering insights to inform corporate development strategies and advance the organization's growth objectives. Michael Fe
Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. "Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda's proven track record makes her an excellent addition to the Daxor team to lead our development projects including our next generation systems, as well as overseeing our operations at our Oak Ridge facility," said Michael Feldschuh, CEO and President of Daxor Corporation. Before joining Daxor, Linda has held several senior leadersh
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
The Hematocrit Feature Will Be Integrated Into A Future Generation Blood Volume Analyzer (BVA)Oak Ridge, TN, July 24, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that Daxor has received a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This additional funding will support adding hematocrit measurement to a future generation blood volume analyzer. The upgrade eliminates the need for hematocrit testing from third-party devices to perform the BVA test.
Daxor's ezBVA Lab Service Emerges as Key Driver for Expansion and Market PenetrationOak Ridge, TN, July 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the expansion of blood volume analysis (BVA). This growth includes launching a BVA program and increasing adoption of Daxor's ezBVA Lab service - a state-of-the-art CLIA certified facility that provides on-demand, next day blood volume analysis results. The company foresees a strong lineup of developments in the second half of this year, reinforcing its trajectory of accelerated sales growth.Recent sales wins include:Regional referral center for Northeast A
Expected to Improve Margins and Increase Revenue Streams Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR), which Iso-Tex has been selling directly to its customer base. Daxor projects the acquisitions to be cash flow positive and accretive to earnings imm
Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Concentrate all your thoughts upon the work in hand. The sun's rays do not burn until brought to a focus." - Alexander Graham Bell We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume meas
Conference Call to be held today at 9:00 AM EST Oak Ridge, TN, March 02, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on March 1, 2023, disclosing its schedule of portfolio holdings as of December 31, 2022. Management reported a NAV of $6.75 per share for fiscal 2022 versus $5.24 for the comparable period in 2021, a $1.51 increase or 36.95%, as well as a 20.5% increase in unaudited revenues and sales for its operating division, which produces and distributes its blood volume analysis (BVA) diagnostic systems and single use test kits which rose by 59.5%. "We a
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)